Falberg’s appointment brings the number of board members to seven who will all stand for reelection at the Annual General Meeting of Shareholders on May 5, 2009.

Falberg also served as CFO of Inamed, a medical device company which was later acquired by Allergan. Former directorships include Human Genome Sciences, Fresh Del Monte and VISX. Falberg currently also serves as chair of the audit committees for Halozyme and ESS Technology.

‘Kate brings a wealth of experience and we are pleased to welcome her to our board,’ said Boyd Clarke, QLT’s Chairman of the Board. ‘Kate brings a robust financial and strategic skill set and strong industry background in biotechnology. We believe that QLT will greatly benefit from Kate’s operational and financial experience.’

Falberg holds B.A. and masters in business administration from the University of California, Los Angeles.

QLT is a Canada-based biopharmaceutical company engaged in discovering, developing and commercialization of therapies.